Data from multiple sources - Curated by Marshall Pearce - Last updated 06 June 2017

Latest news articles

Added 2 days ago Drug news

FDA approves Sutent to treat high risk patients post surgery with renal cell carcinoma

The FDA has approved Sutent (sunitinib malate) for the adjuvant treatment of adult patients who are at a high risk of kidney cancer (renal cell carcinoma) returning after a kidney has been removed (nephrectomy).

Added 8 days ago Drug news

Phase III data on AGS 003 in metastatic renal cell carcinoma shows immune response.- Argos Therapeutics.

Argos Therapeutics provided an update on the immunology data from the February 2017 interim analysis of data from the ongoing...

Search all news articles for Cancer of kidney and renal pelvis
 

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Prostate Cancer

Prostate Cancer

How can you balance the harmful effects of treatment with control of prostate cancer growth in otherwise healthy patients?

+ 5 more

Bedwetting

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting.

+ 7 more

Load more

Guidelines

Guidelines on Renal Cell Carcinoma

The European Association of Urology (EAU) Renal Cell Cancer (RCC) Guidelines Panel has compiled these clinical guidelines to provide urologists...

Added 1 year ago

Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

The ESMO Clinical Practice Guidelines (CPG) are intended to provide the user with a set of recommendations for the best...

Added 3 years ago

Search all guidelines for Cancer of kidney and renal pelvis
 

Journal articles

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.

In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials.

Added 1 month ago

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Background: Sunitinib, a vascular endothelial growth factor pathway inhibitor, is an effective treatment for metastatic renal-cell carcinoma. We sought to determine the efficacy and safety of sunitinib...

Added 1 month ago

Specific immunotherapy in renal cancer: a systematic review.

Renal cell cancer (RCC) is the tenth most common malignancy in adults. In recent years, several approaches of active and passive immunotherapy have been studied extensively in clinical trials of patients with RCC.

Added 6 months ago

Search all journal articles for Cancer of kidney and renal pelvis
 

Clinical trials

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

The purpose of this study is to compare the objective response rate, progression free survival and the overall survival of Nivolumab combined with Ipilimumab to Sunitinib monotherapy in patients with previously untreated Renal Cell Cancer.

Added 4 years ago

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)

This is a trial of AGS-003, which is being studied as a possible treatment for Advanced Renal Cell Carcinoma. The purpose of this study is to determine whether there is an overall survival (OS) benefit between subjects treated with AGS-003...

Added 6 days ago

A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer (S-TRAC)

To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.

Added 1 month ago

Search all clinical trials for Cancer of kidney and renal pelvis
 
Fiona Holland

Fiona worked in the fitness and wellness industry in the US for 13 years, supporting behaviour change in a variety of settings. Fiona’s research interests lie broadly within health and wellbeing. She is particularly interested in qualitative methodologies in the areas of body image ... Read more

What to say and do when someone has cancer

Ahead of World Cancer Day on Saturday (February 4), Fiona Holland, Psychology Lecturer, discusses what to say and what not to say to someone with cancer.